2025-08-05T07:12:24-05:00 2024-12-31 141442607 BST & CO CPAS LLP 10 BRITISH AMERICAN BLVD LATHAM NY 12110 990 2024-01-01 203654626 REGENERATIVE RESEARCH FOUNDATION REGE 5186948188 150 NEW SCOTLAND AVE ALBANY NY 12208 WILLIAM KAHN CPA CHAIR 5186948188 2025-08-05 1 1 NICHOLAS MURABITO P02354743 5184596700 2025-07-28 2024 2025-03-06 01:10:19Z X NEURAL STEM CELL INSTITUTE WILLIAM KAHN CPA 150 NEW SCOTLAND AVE ALBANY NY 12208 7006538 0 X WWW.NEURALSCI.ORG X 2005 NY THE PRINCIPAL MISSION OF THE REGENERATIVE RESEARCH FOUNDATION IS TO DEVELOP REGENERATIVE STEM CELL THERAPIES FOR DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS): THE BRAIN, SPINAL CORD, AND RETINA. 8 7 45 17 0 0 7786967 5982290 700000 782345 57424 75008 250854 166895 8795245 7006538 0 0 0 0 2941974 3003454 0 0 0 4363132 3487594 7305106 6491048 1490139 515490 6996425 9028494 1483775 3000354 5512650 6028140 THE PRINCIPAL MISSION OF THE REGENERATIVE RESEARCH FOUNDATION IS TO DEVELOP REGENERATIVE STEM CELL THERAPIES FOR DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS): THE BRAIN, SPINAL CORD, AND RETINA. 0 0 3316101 531849 FISCAL YEAR 2024 WAS AN EVENTFUL AND PRODUCTIVE YEAR FOR THE REGENERATIVE RESEARCH FOUNDATION. ON OCTOBER 1, 2024 THE FOUNDATION MOVED TO A NEW LABORATORY FACILITY LOCATED IN ALBANY, NY. THE RELOCATION WAS ACCOMPLISHED WITHOUT INCIDENT AND RESEARCH ACTIVITIES RESUMED QUICKLY TO NORMAL LEVELS. FOUNDATION RESEARCHERS PUBLISHED SEVERAL ARTICLES IN PROMINENT SCIENTIFIC JOURNALS REPORTING THE RESULTS OF THEIR INVESTIGATIONS INTO NEURODEGENERATIVE DISEASES SUCH AS DEMENTIA AND POTENTIAL TREATMENTS FOR DISEASES OF THE NERVOUS SYSTEM. THESE PUBLICATIONS WERE MADE FREELY AVAILABLE TO THE RESEARCH COMMUNITY AND GENERAL PUBLIC THROUGH THE NATIONAL LIBRARY OF MEDICINE OPEN ACCESS REPOSITORY. THE FOUNDATION RESEARCHERS WERE ABLE TO SECURE 8 NEW GRANTS WHICH PROVIDE FINANCIAL SUPPORT FOR THEIR RESEARCH ACTIVITIES. 1052191 250496 THE PHASE 1/2A CLINICAL TRIAL COMPLETED ITS FIRST COHORT OF PATIENTS DURING CALENDAR YEAR 2024. THE STUDY CONTINUES TO RECRUIT SUBJECTS AND AT IN DISCUSSIONS WITH A POTENTIAL SECOND CLINICAL SITE WHICH WILL EXPAND THE SUBJECT RECRUITMENT POPULATION. THE PRINCIPAL INVESTIGATOR, DR. JEFFREY STERN, PRESENTED STUDY RESULTS AS AN INVITED SPEAKER AT THE NATIONAL EYE INSTITUTE. THE INSTITUTE WAS ALSO SUCCESSFUL IN OBTAINING REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION FROM THE FDA FOR ITS CELL-BASED THERAPY. 820277 THE ALZHEIMER'S DISEASE AND RELATED DEMENTIAS RESEARCH PROGRAM CONTINUED ITS MISSION TO EXPAND THE UNDERSTANDING AND DEVELOPMENT OF A POTENTIAL TREATMENT FOR THESE NEURODEGENERATIVE DISEASES. THE INSTITUTE SERVES AS THE LEAD ORGANIZATION FOR A CONSORTIUM OF INSTITUTIONS AND INVESTIGATORS FOCUSED ON IDENTIFYING GENES ASSOCIATED WITH THE DEVELOPMENT OF DEMENTIA. THE NATIONAL INSTITUTES OF HEALTH AND SEVERAL PUBLIC CHARITIES SUPPORT THIS UNDERTAKING BOTH PROGRAMMATICALLY AND FINANCIALLY. THE FOUNDATION IS SEEKING BIOTECH PARTNERSHIPS TO SUPPORT RESEARCH AND DEVELOPMENT OF A PROMISING NEURODEGENERATIVE DISEASE TREATMENT. 5188569 1 1 0 0 0 0 0 0 0 0 1 0 0 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 1 1 0 1 45 1 0 0 0 0 0 0 0 0 0 0 0 0 X 8 7 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 1 1 NY X THOMAS J IRWIN 5186948189 150 NEW SCOTLAND AVE ALBANY NY 12208 WILLIAM KAHN CPA CHAIR 5.00 X X 0 0 0 JEFFREY H STERN MD PHD DIRECTOR FOR TRANSLATIONAL 30.00 X X 53025 0 510 JOHN WALSH DIRECTOR 1.00 X 0 0 0 VITO GRASSO MPA CAE DIRECTOR 1.00 X 0 0 0 DAVID O CARPENTER MD DIRECTOR 1.00 X 0 0 0 DAWN ABBUHL DIRECTOR 1.00 X 0 0 0 ROBERT CATALANO MD DIRECTOR 1.00 X 0 0 0 AMY G KLANN PHD JD DIRECTOR 1.00 X 0 0 0 SALLY TEMPLE-STERN PHD SCIENTIFIC & EXECUTIVE DIR 65.00 X 173942 0 21897 CAITLIN HILL PRINCIPAL INVESTIGATOR 40.00 X 135055 0 6756 THOMAS KIEHL PRINCIPAL INVESTIGATOR 40.00 X 131200 0 14982 GLENNA FORD CLINICAL TRIAL MANAGER 40.00 X 139694 0 15319 DAVID BUTLER PHD PRINCIPAL INVESTIGATOR 60.00 X 101541 0 5314 734457 0 64778 5 0 1 0 0 5288818 693472 5982290 SPONSORED RESEARCH 541700 782345 782345 782345 75008 75008 16174 16174 NEURACELL INCOME 541700 145769 145769 OTHER 541700 4952 4952 150721 7006538 782345 0 241903 249374 239582 9792 2316484 1628635 687849 72236 55601 16635 171699 132447 39252 193661 152229 41432 119392 106386 13006 22550 22550 517693 364273 153420 25430 4171 21259 34053 12316 21737 391625 372827 18798 46089 21163 24926 15173 5462 9711 63 63 131965 131965 55430 55430 RESEARCH SUBCONTRACTS 1225862 1225862 LABORATORY CHARGES 734338 636096 98242 EQUIP. REPAIR & MAINT. 113817 89392 24425 MISCELLANEOUS 54114 10162 43952 6491048 5188569 1302479 0 433733 37872 3639688 4962960 1809146 921305 206672 34828 157309 110640 4547955 3813856 486977 734099 262900 2226790 6996425 9028494 1221043 774115 262732 2226239 1483775 3000354 X 4252040 4780002 1260610 1248138 5512650 6028140 6996425 9028494 515490 0 X 0 1 X 1 1 1 X 2767480 4650213 6469338 7786968 5982290 27656289 2767480 4650213 6469338 7786968 5982290 27656289 1676578 25979711 12077 7275 27808 83729 91182 222071 99146 160911 457432 224548 150722 1092759 28971119 3037088 0.89670 0.87540 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: MISCELLANEOUS - 2020 AMOUNT: $ 4,335. 2023 AMOUNT: $ 18,816. 2024 AMOUNT: $ 4,953. NEURACELL INCOME - 2020 AMOUNT: $ 94,811. 2021 AMOUNT: $ 160,911. 2022 AMOUNT: $ 457,432. 2023 AMOUNT: $ 205,732. 2024 AMOUNT: $ 145,769. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 75353 26458 48895 4472602 3787398 685204 734099 OTHER RECEIVABLE 8565 ROU ASSET - OPERATING LEASE (GAAP PRESENTATION PURPOSES ONLY) 2218225 2226790 OPERATING LEASE LIABILITY (GAAP PRESENTATION PURPOSES ONLY) 2226239 2226239 X 7006538 0 7006538 0 7006538 6491048 0 6491048 0 6491048 PART X, LINE 2: THE FOUNDATION FILES FORM 990 ANNUALLY WITH THE INTERNAL REVENUE SERVICE. WHEN ANNUAL RETURNS ARE FILED, SOME TAX POSITIONS TAKEN ARE HIGHLY CERTAIN TO BE SUSTAINED UPON EXAMINATION BY THE TAXING AUTHORITIES, WHILE OTHER TAX POSITIONS ARE SUBJECT TO UNCERTAINTY ABOUT THE TECHNICAL MERITS OF THE POSITION OR AMOUNT OF THE POSITION'S TAX BENEFIT THAT WOULD ULTIMATELY BE SUSTAINED. MANAGEMENT EVALUATED THE FOUNDATION'S TAX POSITIONS, INCLUDING INTEREST AND PENALTIES ATTRIBUTABLE THERETO, AND CONCLUDED THAT THE FOUNDATION HAD TAKEN NO TAX POSITION THAT REQUIRED ADJUSTMENT IN ITS FINANCIAL STATEMENTS AS OF DECEMBER 31, 2024 OR 2023. X X 0 0 0 0 0 0 0 0 0 SALLY TEMPLE-STERN PHD SCIENTIFIC & EXECUTIVE DIR 173942 0 0 0 0 0 7200 0 14697 0 195839 0 0 0 GLENNA FORD CLINICAL TRIAL MANAGER 139694 0 0 0 0 0 5600 0 9719 0 155013 0 0 0 SALLY TEMPLE-STERN SEE PART V 195839 SEE PART V 0 JEFFREY H STERN SEE PART V 53535 SEE PART V 0 SCHEDULE L, PART IV, LINE 1, COLUMN B: SALLY TEMPLE-STERN IS THE EXECUTIVE AND SCIENTIFIC DIRECTOR OF THE ORGANIZATION AND ALSO HAS A FAMILY RELATIONSHIP WITH A CURRENT BOARD MEMBER. SCHEDULE L, PART IV, LINE 1, COLUMN D: SALLY TEMPLE-STERN IS COMPENSATED FOR SERVICES PERFORMED AS THE EXECUTIVE AND SCIENTIFIC DIRECTOR OF THE ORGANIZATION. HER COMPENSATION IS DETERMINED BY THE GOVERNING BOARD AS DISCLOSED IN SCHEDULE O. SCHEDULE L, PART IV, LINE 2, COLUMN B: JEFFREY H. STERN IS THE TRANSLATIONAL RESEARCH DIRECTOR OF THE ORGANIZATION AND ALSO HAS A FAMILY RELATIONSHIP WITH A CURRENT OFFICER. SCHEDULE L, PART IV, LINE 2, COLUMN D: JEFFREY H. STERN IS COMPENSATED FOR SERVICES PERFORMED AS THE TRANSLATIONAL RESEARCH DIRECTOR OF THE ORGANIZATION. HIS COMPENSATION IS DETERMINED BY THE GOVERNING BOARD AS DISCLOSED IN SCHEDULE O. FORM 990, PART VI, SECTION A, LINE 2 DR. JEFFREY STERN AND DR. SALLY TEMPLE-STERN HAVE A FAMILY AND BUSINESS RELATIONSHIP. FORM 990, PART VI, SECTION B, LINE 11B A COPY OF THE ORGANIZATION'S FORM 990 WAS DISTRIBUTED TO AND REVIEWED BY THE BOARD PRIOR TO FILING WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C EVERY BOARD MEMBER IS PROVIDED A COPY OF THE CONFLICT OF INTEREST POLICY AND ALL RELATIONSHIPS INVOLVING AN APPARENT OR POTENTIAL CONFLICT OF INTEREST ARE DISCUSSED BY THE BOARD IN ADVANCE OF THE FOUNDATION ENTERING INTO ANY TRANSACTION OR RELATIONSHIP. THE BOARD ALSO REVIEWS ITS CONFLICT OF INTEREST POLICY ANNUALLY. FORM 990, PART VI, SECTION B, LINE 15 THE COMPENSATION OF ALL EMPLOYEES INCLUDING THE FOUNDATION'S EXECUTIVE DIRECTOR AND OTHER INDIVIDUALS IS REVIEWED AND APPROVED PERIODICALLY BY THE GOVERNING BOARD. THE BOARD CONSIDERS BOTH COMPARATIVE POSITIONS AND GEOGRAPHIC FACTORS WHEN MAKING ITS DECISION. FORM 990, PART VI, SECTION C, LINE 19 ALL FOUNDATION GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE TO THE PUBLIC UPON REQUEST EITHER IN PERSON, BY TELEPHONE OR EMAIL.